In my role as Vice President of International Oncology, I am responsible for driving strategic and operational alignment for all oncology brands across the International region, which encompasses Asia, Middle East & Africa, Latin America, Australia & New Zealand and Russia & Eurasia. Our goal is to push the boundaries of science, change the practice of medicine and to maximise access for patients to transform their lives.
I am most passionate about bringing life-changing medicines to people living with serious diseases. I am particularly proud of the work of our teams at AstraZeneca which, beyond delivering medicines, are focused on supporting the needs of people living with cancer and society at large.
I have spent the last 25 years in the pharmaceutical and consumer goods industries in both country leadership and marketing roles. Since 2012, I have served as President for multiple AstraZeneca country organizations in Southeast Asia, including Vietnam, Malaysia and Singapore. In these respective markets, I was responsible for all aspects of AstraZeneca’s commercial operations, including sales, marketing, regulatory, medical, logistics and finance.
As the immediate past President of the Singapore Association of Pharmaceutical Industries (SAPI), I also gained extensive experience in collaborating with policy makers to make innovative medicines accessible to patients in Singapore.
Prior to joining AstraZeneca, I spent many years at both Johnson & Johnson and Procter & Gamble in the Asia Pacific region where I served in various marketing roles for both pharma and consumer goods divisions. I also previously served as Chairman of the European Chamber of Commerce (EuroCham) Healthcare Committee.
A Singapore national, I was educated and trained as a pharmacist and hold my MBA from the National University of Singapore.
What I find particularly rewarding is bringing life-changing medicines to patients. I’m a firm believer in partnership and believe that continued collaboration with patients, healthcare innovators and organisations will shape the future of healthcare and improve health outcomes for patients around the world.
CURRENT ROLE
2012 - 2020
2010 - 2012
2002 - 2010
Featured publications
Stability of cefazolin sodium eye drops
How TH, Loo WY, Yow KL, Lim LY, Chan EW, Ho PC, Chan SY. Journal of Clinical Pharmacy and Therapeutics. 1998. 23, 41-47.
http://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2710.1998.00136
Cross-cultural differences in infant and toddler sleep
Mindell JA, Sadeh A, Wiegand B, How TH, Goh DYT. Sleep Medicine 11 (2010) 274–280.
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.718.821&rep=rep1&type=pdf
Parental Behaviors and Sleep Outcomes in Infant and Toddlers: A Cross-Cultural Comparison
Mindell JA, Sadeh A, Kohyama J, How TH. Sleep Medicine 11 (2010) 393–399.
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.718.8361&rep=rep1&type=pdf